CADL Stock Price | Candel Therapeutics Inc P/E, Revenue, EPS, & Forecasts

Candel Therapeutics Inc • CADL

Capital at risk.

About
Metrics
Forecasts
Earnings performance
Financial performance
Sentiment analysis
FAQs

About Candel Therapeutics Inc

Ticker

CADL

Trading on

NASDAQ

ISIN

US1374041093

Industry

Biotechnology

Sector

Healthcare

CEO

Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.

Headquarters

117 Kendrick Street, Needham, MA, United States, 02494

Employees

Website

candeltx.com

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma. The company also develops CAN-3110, which is in Phase I clinical trials for the treatment of recurrent high-grade glioma. It also develops the"enLIGHTEN Discovery Platform, a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts.

Metrics

BasicAdvanced

Market cap

$134M

P/E ratio

EPS

-$1.73

Dividend Yield

0.00%

Beta

-0.87

Forward P/E ratio

43.48

EBIDTA

$-34.7M

Ex dividend date

Price & volume

Market cap

$134M

Average daily volume

90-day return

30-day return

7-day return

Dividends

Dividend per share

$0.00

Dividend yield

0.00%

Forward dividend per share

$0.00

Forward dividend yield

0.00%

Payout ratio

0.00%

Valuation

P/E ratio

Forward P/E

43.48

PEG ratio

Trailing P/E

Price to sales

436.42

Price to book

5.85

Earnings

EPS

-$1.73

EPS estimate (current quarter)

$0.00

EPS estimate (next quarter)

$0.00

EBITDA

$-34.7M

Revenues (TTM)

$0M

Revenues per share (TTM)

$0.00

Technicals

Beta

-0.87

52-week High

$14.30

52-week Low

$1.53

50-day moving average

$5.90

200-day moving average

$5.65

Short ratio

7.72

Short %

8.06%

Management effectiveness

ROE (TTM)

480.68%

ROA (TTM)

52.31%

Profit margin

0.00%

Gross profit margin

$-20.7M

Operating margin

0.00%

Growth

Quarterly earnings growth (YoY)

0.00%

Quarterly revenue growth (YoY)

0.00%

Share stats

Outstanding Shares

32.5M

Float

21.7M

Insiders %

30.39%

Institutions %

22.53%

Analyst Insights & forecasts

100% Buy

0% Hold

0% Sell

Based on information from 1 analysts.

Average price target

$11.00

Earnings per share (EPS) forecast

windowbar_chart_4_bars

Actual

Expected

Surprise

-$0.38

-$0.16

137.50%

Q4 • 23Beat

-$0.28

Q1 • 24Beat

-$0.74

Q2 • 24Beat

-$0.33

Q3 • 24Current

QuarterlyAnnual

Financial Performance

windowbar_chart_4_bars

Income StatementBalance SheetCash Flow

windowbar_chart_4_bars

Revenue

Net income

Profit margin

$0M

$-10.6M

∞%

Q3 • 24

$0M

$-14.1M

∞%

Q4 • 24

NaN%

32.19%

NaN%

QoQ growth

QuarterlyAnnual

Totals assets

Total liabilities

Debt to assets

$21.5M

$36.8M

170.91%

Q3 • 24

$107M

$40.5M

37.93%

Q4 • 24

396.66%

10.24%

77.80%

QoQ growth

QuarterlyAnnual

Operating

Investing

Financing

Free cash flow

$-6.6M

$0M

$1.7M

$-6.6M

Q3 • 24

$-5.8M

$-0M

$91.9M

$-5.8M

Q4 • 24

11.55%

∞%

5,380.80%

11.50%

QoQ growth

QuarterlyAnnual

Sentiment analysis

-1.5

Greed

+1.5

0.69

Last 30 days

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Past performance is no guarantee of future results. Your return may be affected by currency fluctuations and applicable fees and charges. The value of your investment may go up as well as down. When investing, your capital at risk.

Build your future fund today!

Automate your wealth-building journey and turn investing into a habit that your future self will be grateful for!

Capital at risk.

FAQs

How much is a Candel Therapeutics Inc share?

Candel Therapeutics Inc shares are currently traded for undefined per share.

How many shares does Candel Therapeutics Inc have?

Candel Therapeutics Inc currently has 32.5M shares.

Does Candel Therapeutics Inc pay dividends?

No, Candel Therapeutics Inc doesn't pay dividends.

What is Candel Therapeutics Inc 52 week high?

Candel Therapeutics Inc 52 week high is $14.30.

What is Candel Therapeutics Inc 52 week low?

Candel Therapeutics Inc 52 week low is $1.53.

What is the 200-day moving average of Candel Therapeutics Inc?

Candel Therapeutics Inc 200-day moving average is $5.65.

Who is Candel Therapeutics Inc CEO?

The CEO of Candel Therapeutics Inc is Dr. Paul-Peter Tak FOCIS, M.D., Ph.D..

How many employees Candel Therapeutics Inc has?

Candel Therapeutics Inc has 38 employees.

What is the market cap of Candel Therapeutics Inc?

The market cap of Candel Therapeutics Inc is $134M.

What is the P/E of Candel Therapeutics Inc?

The current P/E of Candel Therapeutics Inc is null.

What is the EPS of Candel Therapeutics Inc?

The EPS of Candel Therapeutics Inc is -$1.73.

What is the PEG Ratio of Candel Therapeutics Inc?

The PEG Ratio of Candel Therapeutics Inc is null.

What do analysts say about Candel Therapeutics Inc?

According to the analysts Candel Therapeutics Inc is considered a buy.